Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APR-OM32 is an investigational amino acid formulation developed by APR Applied Pharma Research for the management of Tyrosinemia (TYR). The product utilizes APR's proprietary Organic Acid Technology (OAT), a delivery platform designed to improve the sensory properties (taste and smell) and the kinetic profile of amino acid absorption. In Tyrosinemia, patients must adhere to a strict diet low in tyrosine and phenylalanine; APR-OM32 provides the necessary amino acids without these precursors. The OAT formulation aims to mask the unpleasant taste and odor of free amino acids while potentially modulating their release to mimic the absorption of natural proteins, which may lead to more stable plasma amino acid levels and improved metabolic control compared to traditional supplements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on APR-OM32.